Skip to main content
. 2019 Sep 19;216(12):2701–2713. doi: 10.1084/jem.20190738

Figure 1.

Figure 1.

Early corticosteroid treatment reduces antitumor activity by anti–CTLA-4 mAb in a dose-dependent fashion. (A–C) Experimental schema (A) and tumor growth curves (B: mean, C: individual mice) of early corticosteroid treatment. BALB/c mice were inoculated with CMS5a-NY-ESO-1 and injected with anti–CTLA-4 mAb on days 3, 6, and 9 after tumor inoculation. Corticosteroid administration was started on the same day with anti–CTLA-4 mAb (n = 5–11). (D) Representative flow cytometric analysis (left) and summary (right) of NY-ESO-1-tetramer+CD8+ T cells in CMS5a-NY-ESO-1 tumors at 10 d after tumor inoculation (n = 8). L, low dose; H, high dose. (E–G) Experimental schema (E) and tumor growth curves (F: mean; G: individual mice) of late corticosteroid treatment. BALB/c mice were inoculated with CMS5a-NY-ESO-1 and injected with anti–CTLA-4 mAb on days 3, 6, and 9 after tumor inoculation. Corticosteroid administration was started on day 17 (n = 5–7). Data in B and F are mean + SE. Statistical analysis by Dunnett’s test; *, P < 0.05; ***, P < 0.001. These experiments were performed independently three times with similar results.